
Mitapivat raises haemoglobin in sickle cell, not pain crises
10/28/2026
0:00
11:40
Editor's Pick: Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial (The Lancet, 2026)
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning new oral and targeted therapies in non-malignant hematology, a fresh look at treatment strategy in the myeloproliferative neoplasms, and the risks that come with…
This week's papers:
1. Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.. The Lancet 2026.
2. Clinical Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.. American Journal of Hematology 2026.
3. Combination of Thrombopoietin Receptor Agonists and Rituximab in Relapsed/Refractory Immune Thrombocytopenia: A Multicenter Real-World Study.. Journal of Thrombosis and Haemostasis 2026.
4. Emicizumab Prophylaxis in People with Haemophilia A: Summary of Over 13 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy.. Journal of Thrombosis and Haemostasis 2026.
5. Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.. Blood Cancer Journal 2026.
6. High Initial Dose and Accelerated vs. Slow Titration Ropeginterferon Alfa-2b for Polycythemia Vera: A Meta-Analysis.. Blood Advances 2026.
7. New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.. American Journal of Hematology 2026.
8. Hematopoietic Cell Transplantation Outcomes in the Era of Post-Transplant Cyclophosphamide: Comprehensive Donor Analysis.. Blood Advances 2026.
9. Molecular Underpinnings and Prevalence of Donor Cell-Derived Hematologic Neoplasms among Spanish Transplantation Centers.. Blood 2026.
10. Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta-analysis.. British Journal of Haematology 2026.
Listen at https://audioscholar.cc/episode/fnu3j7zm6j
More episodes from "AudioScholar Hematology Weekly (India)"



Don't miss an episode of “AudioScholar Hematology Weekly (India)” and subscribe to it in the GetPodcast app.








